Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Galderma R&D
To determine the safety and efficacy of CD5789 (trifarotene) 50 µg/g cream in the long-term treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a secondary objective.
Age
9–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The Subject has a facial acne severity grade of IGA grade 3 (moderate) at Screening and Baseline visits.
The Subject has a minimum of 20 inflammatory lesions and 25 non-inflammatory lesions at Screening and Baseline visits on the face.
You may not be if
The subject has severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.).
The Subject has more than 1 nodule on the face at Screening and at Baseline visits.
The Subject has any acne cyst on the face at Screening and at Baseline visits.
Clareo Health | CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
